A deep-dive into how pharma companies can apply service operations principles to achieve a greater level of marketing and promotional review committee satisfaction.
A look at the results of recent surveys revealing the impact of the COVID-triggered digital switchover on sales rep interactions and medical conferences.
The importance of expanding your pharma sales forecasting horizon beyond the US. Learn how to effectively navigate country-specific regulatory red flags.
Market dynamics boost the need and urgency for more sophisticated benchmarking strategies.
Companies must determine the right ways to utilize AI.
With technological advancements in affinity tuning and real-time tracking of CAR-T cells, the hope is that CAR-T therapy can be effectively applied to treating solid tumors, improve patient outcomes, and avoid the toxicities seen with certain treatments in the clinic.
How PREP Act protections will apply to potential COVID-19 vaccine-related claims.
Hiring new employees may not be the answer to the war for talent.
There are clear pathways that biopharma companies can take to sustain growth and remain competitive.
Integrating artificial intelligence and advanced analytics throughout operations offers pharma companies a pathway to offset impending drug patent expirations.
Ellenor discusses key points from the recent SCOPE presentation.
Biohaven CEO Vlad Coric talks to Pharm Exec about NURTEC ODT’s swift and seismic impact on the migraine market.
Promotional spending is down as companies rationalize and optimize budgets. But in contrast to big changes on the sales side, marketers are still trying to make the old model work
To increase impact and effectiveness, personalized Web sites should be constructed in different ways to interact with multiple audiences.
Pharma can stand to win hearts, minds, and tax credits by launching an eco bandwagon
Only time will reveal CER's true definition, and determine the full effects of a CER-based system
Everyone has bad days, but do you know how to make the best of them?
The economy is turning around; leaders need to position their companies now for the market bounce.
NHS England is currently undergoing profound changes to introduce a new culture where clinicians and patients are the new stars, where competition is mandatory, where everything rests on patient outcomes and where collaboration and innovation are being encouraged at the highest levels of command.